BioMarin Pharmaceutical Inc., headquartered in San Rafael, California, is a leading biopharmaceutical company that has been transforming lives through genetic discovery since 1997. With a focus on rare genetic diseases, BioMarin develops innovative treatments for patients with previously unmet medical needs. The company's mission is to make a difference by pursuing bold science while respecting, educating, and connecting with patients.

BioMarin's expertise lies in genetics and molecular biology, allowing them to develop targeted therapies that address the root cause of specific conditions. Their groundbreaking discoveries have led to best-in-class treatments and numerous 'firsts' in the field. With a portfolio of products including ROCTAVIAN™, VOXZOGO®, PALYNZIQ®, BRINEURA®, VIMIZIM®, KUVAN®, NAGLAZYME®, and ALDURAZYME®, BioMarin is dedicated to bettering the lives of those struggling with genetic diseases.

Looking ahead, BioMarin aims to expand their impact by applying their science-driven, patient-forward approach to a broader range of genetic disorders. As they continue to develop innovative solutions, BioMarin strives to positively impact more lives in their ongoing mission to transform the lives of patients and families affected by rare genetic diseases